LG

Linda Greub

General Partner at Avestria Ventures

San Francisco Bay Area

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Venture Capital
Start-up Operations
Corporate Development
Strategy
Mergers & Acquisitions
Investment Banking
Equity Research
Capital Markets
Alternative Investments
Hedge Funds
Institutional Investors
Investor Relations
Financial Analysis
Financial Modeling
Management Consulting
Strategic Partnerships
Business Development
Mergers
Start-ups
Commercialization

Education

Lists including Linda

AH
AE
AF
AJ

Based in SF

3077 people

AT
AS
AT
AH

All Series A Investors

14748 people

AM
AT
AS
AR

All Seed Investors

19691 people

Investments

Axena Health

Private Equity

Total Funding: $2M

Fogarty Institute of Innovation

Series A

Total Funding: $5M

Raydiant Oximetry

Series A

Total Funding: $13M

Work Experience

CP
Clarified Precision Medicine

2024

  • Board Member

    2024

MI
Madorra Inc.

2023

  • Board Member

    2023

AV
Avestria Ventures

2018

  • Managing Partner

    2018

    Investing in Early Stage Women's Health and Life Science Ventures

M
Mae

2022

  • Board Member

    2022

AmplifiDx

2021

  • Board Observer

    2021

RO
Raydiant Oximetry, Inc.

2019 - 2024

  • Board Observer

    2019 - 2024

MP
Muir Partners

2016 - 2018

  • CEO

    2016 - 2018

    Life science consulting & financial advisory.

LMN Ventures, LLC

2010 - 2018

  • Partner

    2010 - 2018

    Provided seed capital to early stage companies in Life Science, Education and the Consumer Sector.

RT
RainDance Technologies

2015 - 2016

  • VP Corporate Development

    2015 - 2016

    Led partnership outreach for NGS sample enrichment technology company focused on liquid biopsy for early detection & monitoring of cancer, inherited & infectious disease. Acquired by Bio-Rad.

Singulex

2013 - 2014

  • VP Strategy & Corporate Development

    2013 - 2014

    Redefined corporate strategy for ultra-sensitive protein detection technology company focused on cardiovascular disease and led efforts to sell RUO business unit.